GlassScriptPhysician profile
Lauren M Walter
NPI 1144587148
$1,362.30
in general payments reported to CMS, 2019-2025
20 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $128 · 2023: $307 · 2024: $729 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $283.64 | 2022-2024 | Ubrelvy, Vraylar |
| Gilead Sciences, INC. | $121.27 | 2024 | |
| Glaxosmithkline, LLC. | $104.42 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $95.75 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $92.71 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $84.24 | 2022-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $76.61 | 2024 | Spravato |
| Astellas Pharma US INC | $70.43 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $61.38 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $61.03 | 2023-2025 | Repatha, Repatha, Otezla |
| Dexcom, INC. | $54.02 | 2023-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $41.87 | 2024 | Rybelsus, Ozempic |
| Pfizer INC. | $36.23 | 2024 | |
| Phathom Pharmaceuticals, INC. | $35.80 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $34.93 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.74 | 2022-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $23.48 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.09 | 2024 | Edarbyclor |
| Xeris Pharmaceuticals, INC. | $18.26 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Walter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.